Pharmos Dexanabinol (Correction)
This article was originally published in The Pink Sheet Daily
Executive Summary
Pharmos' Phase III trial for its cannabinoid dexanabinol in traumatic brain injury has completed projected enrollment of about 860 patients in the U.S. and other countries; results are expected by year-end.FDA placed the NMDA antagonist on fast-track status in September 2003. Dexanabinol has never been in clinical development for Parkinson's disease or Alzheimer's disease, as suggested in a story in "The Pink Sheet" DAILY (1"The Pink Sheet" DAILY, March 19, 2004)